Yoneshima et al. (30) found that antinuclear antibody (ANA) positivity had no significant effect on ORR and the incidence of irAEs in NSCLC patients treated with anti-PD-1, but both the median progression-free survival (mPFS) and median overall survival (mOS) were significantly shorter in ANA-positive patients than in ANA-negative patients (2.9 versus 3.8 months, 11.6 versus 15.8 months, p = 0.03 for each instance). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.